Estimating Price Trends For 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP)

60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) does about 5.16M shares in volume on a normal day but saw 3874808 shares change hands in the recent trading day. The company now has a market cap of 2.09M USD. Its current market price is $0.10, marking a decrease of -16.67% compared to the previous close of $0.12. The 52 week high reached by this stock is $1.98 whilst the lowest price level in 52 weeks is $0.10.

60 Degrees Pharmaceuticals Inc (SXTP) has a 20-day trading average at $0.1939 and the current price is -94.77% off the 52-week high compared with 0.68% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2463 and its 200-day simple moving average is $0.4321. If we look at the stock’s price movements over the week, volatility stands at 20.31%, which decreases to 20.21% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 22.54 to suggest the stock is oversold.

The consensus objective for the share price is $1.30, suggesting that the stock has a potential upside of 92.31% over the period.

1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

60 Degrees Pharmaceuticals Inc (SXTP) stock is down -37.25% over the week and -55.23% over the past month. Its price is -89.85% year-to-date and -94.44% over the past year.

The company’s next earnings report forecasts estimating quarterly EPS at -0.23 and -0.47 for whole year. Expected sales for next quarter are $250k, which analysts say will come at $900k for the current fiscal year and next year at $2.55M. In addition, estimates put the company’s current quarterly revenue at an average of $200k.

To reach the target analysts have set, the stock logically needs to grow 92.31 percent from here.

The company has a return on investment of -10.89%. The beta has a value of 3.73. Price to sales ratio is 5.50.